Atlantic Trust Group LLC boosted its stake in Sanofi (NYSE:SNY) by 5.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,870 shares of the company’s stock after buying an additional 2,259 shares during the period. Atlantic Trust Group LLC’s holdings in Sanofi were worth $1,958,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Fisher Asset Management LLC lifted its holdings in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares during the period. Global Financial Private Capital LLC purchased a new stake in Sanofi in the first quarter worth about $35,034,000. Karp Capital Management Corp purchased a new stake in Sanofi in the first quarter worth about $26,174,000. Bank of America Corp DE lifted its holdings in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Sanofi by 25.3% in the first quarter. Parametric Portfolio Associates LLC now owns 1,460,280 shares of the company’s stock worth $66,078,000 after buying an additional 295,242 shares during the period. Institutional investors and hedge funds own 9.33% of the company’s stock.
In other news, major shareholder Sanofi purchased 105,820 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by company insiders.
Shares of Sanofi (NYSE SNY) opened at 49.37 on Friday. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company has a market cap of $123.99 billion, a P/E ratio of 11.76 and a beta of 0.88. The firm has a 50-day moving average of $48.20 and a 200-day moving average of $47.11.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue was down 2.3% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post $3.34 earnings per share for the current year.
Several research firms have recently issued reports on SNY. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Friday, June 2nd. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reiterated a “buy” rating and set a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. Finally, Cowen and Company reiterated a “market perform” rating and set a $52.00 target price (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $54.00.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.